HB3605ham002 104TH GENERAL ASSEMBLY

Rep. Camille Y. Lilly

Filed: 3/16/2026

10400HB3605ham002 LRB104 09298 BAB 35578 a

AMENDMENT TO HOUSE BILL 3605

AMENDMENT NO. ______. Amend House Bill 3605, AS AMENDED, by replacing everything after the enacting clause with the following:

"Section 5. The Illinois Insurance Code is amended by changing Section 356u.10 as follows:

(215 ILCS 5/356u.10)

Sec. 356u.10. Genetic testing and evidence-based screenings for an inherited gene mutation.

(a) As used in In this Section: ,

"Cost sharing" means a deductible, coinsurance, copayment, or any similar out-of-pocket expense.

"Evidence-based cancer screening" means evidence-based cancer screening modalities in accordance with the most recent version of the National Comprehensive Cancer Network clinical practice guidelines.

"Genetic genetic testing for an inherited mutation" means germline multi-gene testing for an inherited mutation associated with an increased risk of cancer in accordance with evidence-based, clinical practice guidelines.

(b) A group policy of accident and health insurance or managed care plan that is amended, delivered, issued, or renewed after January 1, 2027 2026 shall provide coverage for clinical genetic testing for an inherited gene mutation for individuals with a personal or family history of cancer, as recommended by a health care professional in accordance with current evidence-based clinical practice guidelines, including, but not limited to, the current version of the National Comprehensive Cancer Network clinical practice guidelines. The coverage shall limit the total amount that a covered person is required to pay for a clinical genetic test under this subsection to an amount not to exceed $50, except for services for which cost sharing is prohibited under 42 U.S.C. 300gg-13. This subsection (b) shall not apply to coverage of genetic testing to the extent such coverage would disqualify a high-deductible health plan from eligibility for a health savings account pursuant to Section 223 of the Internal Revenue Code.

(c) For individuals with a genetic test that is positive for an inherited mutation associated with an increased risk of cancer, coverage required under this Section shall include any evidence-based screenings, as recommended by a health care professional in accordance with current evidence-based clinical practice guidelines, including, but not limited to, the current version of the National Comprehensive Cancer Network clinical practice guidelines, to the extent that the management recommendation is not already covered by the policy. , except that coverage for evidence-based screenings under this subsection (c) may be subject to a deductible, coinsurance, or other cost-sharing limitation so long as the limitation is not greater than that required for other related cancer risk management benefits covered under the policy. In this subsection, "evidence-based cancer screenings" means medically recommended evidence-based screening modalities in accordance with current clinical practice guidelines.

(d) The coverage provided in subsections (b) and (c) shall be provided without cost sharing, except for services for which cost sharing is prohibited under 42 U.S.C. 300gg-13. Subsections (b) and (c) do not apply to the extent that providing such coverage would disqualify a high-deductible health plan from eligibility for a health savings account pursuant to Section 223 of the Internal Revenue Code.

(Source: P.A. 103-914, eff. 1-1-25.)".